Titan Health Partners, LLC – Trademark Portfolio

Entity Type: 16

Titan Health Partners, LLC holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 13 filings in this category. Currently, 11 trademarks are registered and 2 are pending. Notable registered marks include ASTERA, ASTERA UROLOGY, ASTERA BREAST CARE, ASTERA CANCER CARE, and ASTERA INFUSION SERVICES. The owner is based in East Brunswick, NJ.

629 Cranbury Road 2nd Floor

East Brunswick, NJ 08816

13 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Titan Health Partners, LLC's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

44
Medical Services (13 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does Titan Health Partners, LLC have?

Titan Health Partners, LLC has 13 U.S. trademarks filed with the USPTO. Of these, 11 registered, 2 pending.

What trademark classes does Titan Health Partners, LLC file in?

Titan Health Partners, LLC files trademarks across 1 Nice Classification class. The most active classes are Class 44 (Medical Services). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.

What are Titan Health Partners, LLC's most well-known trademarks?

Titan Health Partners, LLC's registered trademark portfolio includes well-known marks such as ASTERA, ASTERA UROLOGY, ASTERA BREAST CARE, ASTERA CANCER CARE, and ASTERA INFUSION SERVICES. These are among 11 currently registered trademarks in the portfolio.

What is Titan Health Partners, LLC's trademark registration success rate?

Titan Health Partners, LLC has a 100% trademark registration rate, with 11 out of 11 resolved applications resulting in successful registration. Currently, 2 applications are pending review.